Get the latest delivered to your inbox
Privacy Policy

Now Reading

New Coalition Aims To Close The Opportunity Gap In Bioscience

Bioscience & Investor Inclusion Group (BIIG) founding members include Liftstream, New England Venture Capital Association, Third Rock Ventures, Biogen and BioDirector

New Coalition Aims To Close The Opportunity Gap In Bioscience

Bioscience & Investor Inclusion Group (BIIG) founding members include Liftstream, New England Venture Capital Association, Third Rock Ventures, Biogen and BioDirector

Published 12-04-20

Submitted by Biogen

  • Coalition aims to advance diversity, equity and inclusion in the life sciences venture capital industry and its associated portfolio companies
  • Members commit to developing solutions to increase participation among underrepresented groups and driving measurable change in the VC industry and among innovator companies

BOSTON, December 4, 2020 /CSRwire/ -- Liftstream, New England Venture Capital Association (NEVCA), Third Rock Ventures, Biogen Inc. (NASDAQ: BIIB) and BioDirector today announced Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion (DE&I) in the life sciences sector.

Funding for female founders hit its lowest quarterly total in three years1 and only 2.6 percent of total VC funding in 2020 went to Black and Latinx founders2. To address these gaps in the life sciences sector, BIIG brings together leaders with a range of industry perspectives including R&D, commercialization, human capital, venture investing and corporate governance.

“Diverse teams strengthen companies and spur innovation, yet minorities are historically underfunded as entrepreneurs and underrepresented in startup leadership. This is partly attributable to only 11 percent of venture investment partners being women and just 3 percent from racial and ethnic minorities,” says Jody Rose, President, NEVCA. “It is vital for the life sciences sector to become more inclusive and focus on solutions that accelerate change.”

BIIG was formed after an executive forum hosted by the organizations outlined critical practices for advancing the representation of women and minorities in the workplace. The participants are committed to change and will share proven practices to develop solutions for the entire sector.

“Inclusion can only be achieved in the life sciences sector if venture investors actively participate in changing the composition of their partnerships. BIIG will engage the investment community to create and deploy solutions that not only improve capital allocation to women and minorities but will make inclusion a strategic imperative as they exert influence upon the company-building process,” said Karl Simpson, CEO, Liftstream. “While there is positive intent, the complexity of the DE&I opportunities, compounded by the lack of diverse representation in designing solutions, inhibits real progress.”

Dedicated workstreams, served by a voluntary group of industry leaders, will seek to deliver solutions for target areas such as: people growth and retention, hiring and onboarding, and investor interactions.

“By shining the spotlight on this significant, unsustainable gap, the life sciences industry – already known for innovation – will broaden our understanding of the market and uncover even more ingenuity and opportunities to discover and develop potentially life changing therapies,” said Minita Shah-Mara, VP of Organization Effectiveness and Diversity, Equity & Inclusion, Biogen.

BIIG is open to individuals and companies interested in joining the founding members in the pursuit of a more diverse, equitable and inclusive industry. To learn about how to get involved, please visit: www.bioinclusion.org.

1. Pitchbook: Quarterly VC funding for female founders drops to three-year low: https://pitchbook.com/news/articles/vc-funding-female-founders-drops-low
2. 2020 Crunchbase Diversity Spotlight Report: https://about.crunchbase.com/2020-diversity-spotlight-report/

Biogen Logo

Biogen

Biogen

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

More from Biogen

Join today and get the latest delivered to your inbox